Want to see IL:INCR full AI Analyst Report?
Intercure (INCR) AI Stock Analysis
Intercure
(TASE:INCR)
The overall score is held down by weak financial performance, characterized by compressed margins, persistent net losses, and historically volatile cash generation despite a recent return to positive free cash flow. This is partially offset by a reasonably robust balance sheet with moderate leverage and by constructive technical momentum, as the stock trades above key moving averages with supportive trend indicators. Valuation offers limited current support given the negative P/E and lack of dividend, so the investment case rests on a successful operational turnaround rather than present earnings strength.
Intercure (INCR) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 155.06M
- Dividend Yield
- ―
- Average Volume (3M)
- 22.61K
- Price to Earnings (P/E)
- -3.9
- Beta (1Y)
- 0.46
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Israel
- Employees
- 285
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Intercure Business Overview & Revenue Model
Company Description
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to prod...
How the Company Makes Money
InterCure primarily makes money by selling medical cannabis products and related cannabis-based wellness products in Israel. Key revenue streams include: (1) sales of medical cannabis products to patients via retail/dispensing channels, including com...
Intercure Financial Statement Overview
Summary
Financial performance is weak overall: revenue has only modestly recovered from prior declines, margins have compressed sharply, and the business remains loss-making with negative EBITDA, but a moderately solid equity base, improving debt-to-equity in 2025, and a return to positive operating and free cash flow provide some support.
Income Statement
33NegativeBalance Sheet
60NeutralCash Flow
47Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 270.20M | 270.20M | 238.84M | 355.55M | 388.68M | 219.68M |
| Gross Profit | 40.70M | 33.18M | 30.23M | 105.09M | 155.08M | 91.13M |
| EBITDA | -50.09M | -7.29M | -51.31M | -23.90M | 70.23M | 31.17M |
| Net Income | -35.71M | -35.71M | -67.80M | -61.96M | 44.82M | 4.69M |
Balance Sheet | ||||||
| Total Assets | 690.55M | 690.55M | 762.57M | 786.61M | 958.01M | 686.32M |
| Cash, Cash Equivalents and Short-Term Investments | 46.67M | 46.67M | 78.65M | 101.33M | 232.79M | 196.55M |
| Total Debt | 183.01M | 183.01M | 211.40M | 195.68M | 255.16M | 108.91M |
| Total Liabilities | 294.19M | 294.19M | 364.90M | 329.55M | 436.53M | 227.13M |
| Stockholders Equity | 396.52M | 396.52M | 396.97M | 455.11M | 501.31M | 448.03M |
Cash Flow | ||||||
| Free Cash Flow | 13.29M | 13.29M | -71.30M | -56.25M | 31.52M | 10.99M |
| Operating Cash Flow | 16.84M | 16.84M | -66.93M | -53.63M | 51.27M | 25.02M |
| Investing Cash Flow | -1.99M | -1.99M | 17.69M | 4.77M | -142.50M | -65.21M |
| Financing Cash Flow | -46.66M | -46.66M | 26.45M | -82.89M | 120.45M | 197.94M |
Intercure Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:INCR, the sentiment is Negative. The current price of 1309.00 is below the 20-day moving average (MA) of 1485.55, below the 50-day MA of 1563.50, and below the 200-day MA of 1434.04, indicating a bearish trend. The MACD of -70.38 indicates Positive momentum. The RSI at 27.91 is Positive, neither overbought nor oversold. The STOCH value of 19.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:INCR.
Intercure Peers Comparison
Overall Rating
- IL:INCR54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IL:INCR | 54Neutral | ILS 162.17M | -3.94 | -8.77% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:INCR | Intercure | 1309.00 | -996.50 | -43.22% | |
| IL:TGTR | Together Pharma Ltd. | 187.90 | -129.60 | -40.82% | |
| IL:CNZN.M | Canzon-M | 89.90 | -11.90 | -11.69% | |
| IL:SEMG | Seach Medical Group Ltd. | 261.50 | -0.97 | -0.37% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 25, 2026